CLINICAL TRIAL

Treatment for Relapse

1 Prior Treatment
Recurrent
Stage I
Recruiting · 18+ · Female · Seattle, WA

This study is evaluating whether social support can improve treatment completion for Black patients with endometrial cancer.

See full description

About the trial for Relapse

Eligible Conditions
Endometrial Neoplasms · Recurrence · Endometrial Cancer

Treatment Groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Control Group 1
Facilitated group support
BEHAVIORAL
Control Group 2
1:1 Peer Support
BEHAVIORAL

Eligibility

This trial is for female patients aged 18 and older. You must have received 1 prior treatment for Relapse or one of the other 2 conditions listed above. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Recurrent endometrial cancer of any stage or grade
Adult 18 years of age or older;
Self-identify as Black/African American
Pathology documentation from any hospital/clinic/medical center,
FIGO Stage 1A with Grade 2, Grade 3, or Grade 4 of any histology type or FIGO Stage 1A with non-endometrioid (carcinosarcoma, serous, clear cell, undifferentiated or mixed) histology
FIGO Stage 1B, 2, 3, or 4 of any grade or histology
Documented provider recommendation and patient plan to initiate adjuvant therapy with chemotherapy, radiation, and/or immunotherapy.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 6 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 6 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 1 primary outcome and 1 secondary outcome in patients with Relapse. Measurement will happen over the course of 6 months.

Treatment completion (relative dose)
6 MONTHS
Relative dose is the ratio of actual-to-expected total dose of treatment received. The calculation of expected total dose will be made from the baseline treatment recommendation data collected at enrollment.
6 MONTHS
Patient-reported social isolation (SPS-24)
6 MONTHS
The Social Provisions Scale (SPS) is one of the most frequently used scales on social support, and is validated to measure the components of social support that directly impact health outcomes: attachment, social integration, reassurance of worth, reliable alliance, guidance, and opportunity for nurturance.
6 MONTHS

Who is running the study

Principal Investigator
K. D.
Prof. Kemi Doll, Assistant Professor, School of Medicine
University of Washington

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have there been other clinical trials involving treatment?

Recent findings of this prospective study suggest that the majority of patients undergoing chemotherapy were enrolled in clinical trials, and the number of patients receiving therapies from these studies increased significantly during the time frame studied. However, a significant number of patients did not receive any of these therapies; therefore, continued efforts at identifying and recruiting patients into clinical trials would be beneficial.

Anonymous Patient Answer

What is treatment?

This article describes a number of elements necessary for effective treatment of SLE patients with active disease; however, the conclusions are limited by the authors' lack of experience with this topic. Further research into the most effective treatment options for SLE is needed.

Anonymous Patient Answer

Who should consider clinical trials for relapse?

Those with high risk factors for relapse may benefit from clinical trials if their disease status remains stable at least 6 months after therapy. Patients who experienced relapse within 6 months of treatment may be candidates for early intervention through clinical trials.

Anonymous Patient Answer

What are the signs of relapse?

The exact time at which symptoms first begin to return after a prolonged remission was not determined. We need more evidence on when to begin treatment again if the patient has not had a relapse yet.

Anonymous Patient Answer

What are the chances of developing relapse?

Relapse rates vary based on patient characteristics, such as age, gender, ethnicity, and weight gain. The relapses after remission are usually milder than those before remission. However, while patients generally develop fewer relapses than before remission, they still face a higher risk of development of relapse compared to their healthy peers. Thus, clinicians should keep in mind the possibility of further relapse even if patients seem to have recovered.

Anonymous Patient Answer

How quickly does relapse spread?

Findings from a recent study suggest that relapse tends to spread at a similar rate as other chronic diseases, although rapid spread may be possible for some relapse subtypes. Findings from a recent study suggest that relapses should be treated aggressively in order to reduce further spread of relapse.

Anonymous Patient Answer

How many people get relapse a year in the United States?

For the first time since 1992, the number of people with relapsed prostate cancer is rising. It's important to remember that many people with prostate cancer relapse without being aware they have the disease. It's also important to understand that one person can have multiple relapses. Today's average age of men diagnosed with prostate cancer is around 70 years old - yet over half of men will go on to develop a relapse....So it's important to address these facts when evaluating everyone for prostate cancer treatment.

Anonymous Patient Answer

What are the latest developments in treatment for therapeutic use?

The current treatment options are not satisfactory. About 80% of patients over the age of 65 require more than one medication to control their symptoms. Some patients need a high dosage of dopamine agonists because they do not respond to levodopa. In addition, many patients suffer from refractory dyskinesia (persistent involuntary movements) that persist despite optimal therapy. These patients may benefit from switching to subcutaneous apomorphine infusion, which eliminates the need for an oral formulation. Apomorphine is being studied beyond its original indication in Parkinson's disease for other indications such as restless legs syndrome.

Anonymous Patient Answer

What does treatment usually treat?

Recent findings indicate that patients treated at a specialty center are significantly more likely to achieve remission or sustained response than those treated at nonspecialty centers. Additional research needs to investigate whether this difference is related to differences in treatment intensity or duration.

Anonymous Patient Answer

How serious can relapse be?

Results from a recent paper suggests that relapses are not as serious as feared. It also confirms that complete remission is an important goal when treating multiple myeloma and that all patients need continual surveillance with blood tests and imaging.

Anonymous Patient Answer

What causes relapse?

Patients who have had a complete remission after initial therapy appear at high risk for relapse. Relapse seems to be related to certain features of disease such as genetic markers, histology, and the stage at which overt relapse occurs. The use of specific immunologic parameters and clinical variables may help to identify patients at high risk for relapse. The role of chemotherapy in the management of recurrent disease remains unclear; however, anecdotal evidence suggests that repeated treatment with systemic chemotherapy may delay time to first recurrence until patients become symptomatic.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Relapse by sharing your contact details with the study coordinator.